Astrazeneca plc, of London, and its biologics research arm, Medimmune, reported that the phase III FALCON trial demonstrated superiority of Faslodex (fulvestrant) over Arimidex (anastrozole) in the first-line treatment of hormone receptor-positive advanced breast cancer. Data are being presented at the European Society for Medical Oncology in Copenhagen.